Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserv⦠read more
Healthcare
Drug ManufacturersāSpecialty & Generic
6 years
USD
Exclusive to Premium users
$4.00
Price+1.27%
$0.05
$507.431m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$429.531m
-
1y CAGR-
3y CAGR-
5y CAGR-$10.979m
-
1y CAGR-
3y CAGR-
5y CAGR-$0.12
-
1y CAGR-
3y CAGR-
5y CAGR$361.219m
$461.128m
Assets$99.909m
Liabilities$40.816m
Debt8.9%
-2.9x
Debt to EBITDA-$46.370m
-
1y CAGR-
3y CAGR-
5y CAGR